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ABSTRACT 
The work was aimed to develope the meter dose formulation of pediatric xylometazoline nasal spray formulation. The 32 factorial 
design was utilized for development of the pediatric formulation. The independent factors were sodium cholate (X1) and 
Polyethyleneglycol 400 concentration (X2). The optimized formulation composition consisted of 0.105 g sodium cholate and 1.35 ml 
polyethyleneglycol 400. The formulation was evaluated for solution parameters like drug content, pH, viscosity, % diffusion, 
sterility and spray evaluation parameters like spray content uniformity, pump delivery, spray pattern, and weight loss. The results for 
spray content uniformity were in the range of 95-102 %, while pH in the range of 6.5 ± 0.3. The ovality of spray was 1.118, while 
perimeter and area of spray pattern were found to be 57.42 mm and 258.8 mm2 respectively for optimized formulation. The least 
value for repriming was 97.6 % while the extreme value was 102.2 % indicating one actuation was satisfactory for repriming. The 
results for droplet size test were obtained in the range of 51.63 to 58.90 µm. The formulation along with its container closure was 
evaluated for its stability up to 12 months at long term conditions. The formulated batch PFE showed better performance for in-vitro 
drug release with marketed product thus providing another option for treatment of nasal congestion. 
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INTRODUCTION 
The pharmaceutical arena is constantly in search for 
novel drug delivery systems that can overwhelm the 
existing issues. The suitability of administration and 
enhanced patient amenableness are essential in the 
strategy of nasal drug delivery system. 
1,2
 About 2% of 
the drugs that are conveyed through nasal route due to 
the reason for availability of large surface area. In 
comparison to alternative routes of drug delivery, nasal 
route is found more prominent. 
3,4, 5.
 
There is wide range of differences observed between 
adults and children in various aspects of 
pharmacotherapy which are mandatory for achieving 
accurate and safe dosage administration. The drug 
product formulated for pediatric use must take into 
consideration factors such as age targeted, physiological 
conditions and type of requirement of treatment. Some 
advancement in development of pediatric formulations is 
observed due to new regulations, as well as collaborative 
research work. Allergic rhinits or sinusitis has one 
indication as nasal congestion in pediatric patients. 
6
 
Drug substance like xylometazoline, which is of 
imidazole class, acts on alpha-adrenergic receptors of 
nasal mucosal arterioles leading to decrease of blood 
flow. It reduces the swelling of nasal turbinate’s, relating 
to amplification of nasal lumen.
 7,8,9
 Various excipients 
were used in novel drug delivery system with aim of 
taking specific roles in drug delivery system such as 
carriers, bioavailability enhancers, masking of taste, 
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stabilizer, solubilizer etc. In recent days, various natural 
as well as synthetic polymers are widely used in nasal 
drug delivery. The present work described the 
formulation development and evaluation of nasal 
solution dosage form for pediatric use of xylometazoline 
as a model drug. The meter dose spray formulation helps 
to deliver known amount of formulation.  
MATERIALS AND METHODS 
Materials 
Xylometazoline hydrochloride was procured from Anish 
Chemicals, Gujarat, India. Sodium cholate from 
National Chemicals Pvt. Ltd, Vadodara, India,  PEG 400 
from Sigma Aldrich, USA. Methyl Paraben from S.D. 
Fine Chem. Ltd, Mumbai, India and Sodium 
carboxymethyl cellulose from Amar cellulose industries, 
Gujarat, India. The container closure system was 
obtained from Aptar Pharma, Mumbai, India.  
Methods 
Preparation of Xylometazoline pediatric nasal solution: 
The pediatric nasal solution was prepared by sequential 
mixing of various excipients as shown in Figure 1.
 
 
Figure 1: Method of preparation of nasal solution 
 
Experimental Design 
A 3 level 2 factors factorial design (3
2
) was adopted 
using concentration of sodium cholate (X1) and PEG 400 
(X2) as independent variables for formulation 
development of pediatric xylometazoline nasal solution. 
(Stat- Ease Design Expert®, v 9). The levels of 
independent variables were designated as depicted in 
Table 1 and all the batches were formulated conferring 
to experimental design (Table 2). The batches were then 
assessed for different parameters.  
Equation 1 below demonstrations the polynomial 
equation for 3
2
 experimental design.   
                          ……(Eq.1)                                 
 Where Y = dependent variable 
β0 = Intercept (arithmetic mean of all the batches) runs,                                                           
β1 = estimated coefficient for the factor X1. 
Β2-Estimated coefficient for the factor X2 
Β12= Estimated coefficient of the interaction between 
X1 and X2 
 
Table 1: Independent variables and their levels for Xylometazoline Solution for Pediatric Use 
Level Independent Variables 
X1= Concentration of Sodium 
Cholate (g) 
X2 = Concentration of PEG 
400 (ml) 
1(Low Level) 0.02  0.50  
0 (Medium Level) 0.07  1.00  
+1 (High level) 0.12  1.50  
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Table 2: Composition of 3
2 
factorial design of Pediatric use nasal formulations of xylometazoline* 
Batch X1, Sodium Cholate 
Concentration (g) 
X2, PEG 400 
Concentration (ml) 
X1 X2 
PFA1 0.02 0.5 -1 -1 
PFA2 0.07 0.5 0 -1 
PFA3 0.12 0.5 1 -1 
PFA4 0.02 1.0 -1 0 
PFA5 0.07 1.0 0 0 
PFA6 0.12 1.0 1 0 
PFA7 0.02 1.5 -1 1 
PFA8 0.07 1.5 0 1 
PFA9 0.12 1.5 1 1 
* Each factorial design batch contained 10 mg of xylometazoline, 0.01 g of Na CMC, 0.15 ml of Glycerin, 0.0033g Methyl Paraben, 
q.s. of NaCl, and volume was made with purified water to 10 ml 
 
Evaluation parameters of formulation: 
Clarity: 
The formulated solutions were evaluated as in-house test 
for clarity. The color and clarity were visually examined 
against black and white surface in inspection booth. 
10
 
Drug Content: 
The drug content of the nasal formulation was measured 
using standard curve equation obtained by calibration 
curve using UV spectrophotometer at 268 nm. The 
sample of the formulation was diluted using distilled 
water and absorbance was measured at 268 nm using 
water as blank. The mean of three results was used as 
drug content of the sample. 
11
  
pH: 
The pH was measured in triplicate for pH using digital 
pH meter. The model pH range of nasal formulations 
was in range of 6.5 ± 0.3.
 12,13,14
 
Viscosity: 
Viscosity has influence on the dwelling time of 
formulation, which is associated to rate of drug 
absorption through nasal mucosa. The viscosity was 
measured through Brookfield Viscometer (Spindle no 
S18 at 100 rpm) (Brookfield Viscometer, Model no DV-
II PRO, Dolphine instrument, Mumbai). 
10
 
Spray Content Uniformity: 
The spray content uniformity as critical parameter for 
nasal spray, was studied to explore the spray discharged 
containing the amount of active ingredient from the 
nosepiece. The examination was carried out for multiple 
spray form single container and in different container for 
the same. The acceptance criteria was defined as the 
amount of active ingredient not outside of 80-120 
percent of label claim for more than 1 of 10 containers, 
none of the determinations is outside of 75–125 percent 
of the label claim, and the mean is not outside of 85-115 
percent of label claim. 
15,16
 
Pump Delivery: 
The pump delivery is crucial parameter interrelated with 
spray content uniformity for product performance. The 
pediatric nasal spray formulation was assessed for 
pump-to-pump reproducibility and the pump metering 
capability. The formulation was actuated for 10 times in 
a pre-weighed bottle. The bottle was reweighed after 10 
actuations and the difference was calculated. 
10
 
Spray Pattern: 
Spray Pattern of prepared nasal spray formulation was 
measured by the SprayVIEW system (Proveris Scientific 
Corperation, USA) furnished with the SprayVIEW 
automated pump actuation system. The parameters of 
spray pattern assessment are height at 30 mm, 
evacuation time 15000 millisecond, inclination as 65.4
o
 
and summation mode as automatic. 
15,16
 
Weight Loss: 
The weight loss is parameters that determines the 
product performance and stability. Inverted and 
Horizontal positions shows noteworthy role in weight 
loss, hence both orientations were kept for the drug 
product storage. The weight loss of formulation in the 
container closure system was determined as per USP 
chapter <755> and it is essentially to be in accordance 
with the predefined specification. 
11,15,17
 
Priming and Repriming: 
The first priming essentially to demonstrate the 
minimum amount of drug released from the product, 
while repriming shows the ability of product to delivery 
same amount of drug content after storage of product. 
The length of storage for conducting the study is defined 
as 5, 10 and 30 days. The number of actuations are 
determined that are required for priming until the 
subsequent doses meet the specification limits (80-120 
% label claim). The number of actuations are determined 
that are required for re-priming up to the subsequent 
doses meets the specification limits. 
11, 16
 
In-vitro Diffusion: 
This study was performed using the Franz diffusion cell, 
where recently isolated sheep nasal mucosa obtained 
from a local slaughter house was utilized for attachment 
on diffusion chamber. The doner medium comprised of 
formulation, while the receptor medium comprised of 
phosphate buffer, while the temperature of the medium 
was maintained at 37 
o
C ± 1 
o
C. The receptor medium 
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was refilled with the equivalent volume of the fresh 
solution as the samples withdrawn. The samples were 
then analyzed spectrophotometrically at a wavelength of 
265 nm against blank. The obtained results are compared 
with the current marketed formulation Otrivin® 
Pediatric (Novartis). 
18,19,20,25
 
Droplet Size Distribution: 
The deposition of the nasal formulation in cavity is 
impacted by droplet size distribution of the spray. The 
delivery device and the formulation are the two major 
factors that influence the droplet size. There must be 
appropriate control for droplet size distribution of the 
delivered plume. The droplet size distribution can be 
measured in terms of D10, D50, and D90 by utilization 
of laser diffraction. 
21,22
 
Sterility: 
Sterility is an important requirement for nasal 
formulation. The method used was as per USP chapter 
for sterility tests <71>. 
23
 
Stability study: 
The stability studies were executed at 25 ± 2 
o
C/ 60 ± 
5% RH for stability stations 3, 6, 9 and 12 months for 
long term studies, while at 40 ± 2 
o
C/ 75 ± 5% RH for 
accelerated studies at stations 3 and 6 months. 
24
 
 
RESULTS AND DISCUSSION 
Preliminary trials and composition of nasal 
formulation 
The preliminary formulation trials were designed for the 
selection of surfactant concentration, and co-solvent 
amount. The preliminary parameters like clarity, pH, 
drug content, % diffusion at 10 minutes and viscosity 
were optimized by varying one parameter at a time, 
while keeping the others constant, so that the effect of 
varied parameter could be evaluated. The concentration 
range 0.02 g to 0.12 g of sodium cholate as surfactant 
was selected, while the concentration range of 0.50 ml to 
1.50 ml of polyethylene glycol 400 was selected for 
further studies. 
Experimental design 
Pediatric nasal solution was formulated by utilizing 3
2
 
factorial design.  These batches were assessed using 
polynomial equation of design and two check point 
batches were confirmatory for authentication of design 
of experiment. The assessment tests parameters 
consisted for appearance, pH, viscosity, drug content 
and % diffusion at 10 minutes (Table 3). The % 
diffusion at 10 minutes and viscosity displayed 
differences based on the values of independent variables, 
henceforward they were defined as dependent 
parameters.
 
Table 3: Results of responses of 3
2
 factorial design of pediatric xylometazoline nasal solution 
               Parameter: → 
Batch * 
↓ 
% Diffusion at 10 minutes [Y1] Viscosity  
(cp)[Y2] 
PFA1 65.33 ± 1.52 13.33 ± 0.57 
PFA2 74.33 ± 1.52 14.33 ± 1.15 
PFA3 90.33 ± 0.57 15.33 ± 0.57 
PFA4 64.33 ± 1.15 17.00 ± 1.00 
PFA5 75.33 ± 0.57 18.33 ± 0.57 
PFA6 93.33 ± 0.57 18.33 ± 0.57 
PFA7 66.66 ± 0.57 21.33 ± 0.57 
PFA8 76.33 ± 1.52 19.33 ± 0.57 
PFA9 91.66 ± 1.52 20.00 ± 1.73 
 
The polynomial equation was obtained by regression analysis of the results of % diffusion at 10 minutes for 3
2
 factorial 
design batches by equation 3: 
                                                                                            …(Eq.3) 
\
Among the independent variables, X1 had prominent 
positive effect (β1= 13.1666) on diffusion at 10 minutes. 
The X2 variable had very less effect (β2= 0.7777), while 
the interaction between X1 and X2 showed no impact on 
diffusion at 10 minutes (β12= 0.00). Sodium cholate 
exhibited prominent impact on % diffusion at ten 
minutes. The contour and surface response plot for % 
diffusion at 10 minutes were displayed in Figure 2. It 
could be inferred from the contour and response surface 
plot that excipient sodium cholate has correlation to % 
diffusion at 10 minutes. 
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Figure 2: Contour and Response Surface Plots for % Diffusion and viscosity 
 
The data of model summary statistic for % diffusion at 
10 minutes (Y1) clearly suggest the quadratic model 
shows better suitability as compared to other statistic 
models. The Table 4 displays the independent variables 
impact on the percentage diffusion at 10 minutes. The 
data obtained reveals that the p-value < 0.05 stating that 
the factor has significant impact on dependent 
parameter. Hence conclusion can be derived that sodium 
cholate have substantial impact on diffusion rate on 
formulation.
 
Table 4: ANOVA for % Diffusion at 10 minutes 
 
Source 
Sum of 
Squares 
 
df 
Mean 
Square 
F 
Value 
p-value 
Prob > F 
Coefficient 
  
Model 1065.38 5 213.07 115.57 0.0012 
(significant) 
 
Intercept[(β0)]      75.4814 
Sodium cholate [(β1)] 1040.17 1 1040.17 564.00 0.0001 13.1666 
PEG 400[(β2)] 3.62 1 3.62 1.96 0.2551 0.7777 
 [(β12)] 0.000 1 0.000 0.000 1.0000 0.0000 
 [(β1)
2
]
 
21.47 1 21.47 11.64 0.0420 3.2777 
[(β2)
2
] 0.100 1 0.100 0.054 0.8318  0.2222 
Residual 5.53 3 1.843      
Cor Total 1070.91 8         
 
The polynomial equation 4 was obtained by regression 
analysis of the results of viscosity for 3
2
 factorial design 
batches as below: 
                                        
                                               
……(Eq.4) 
The quadratic model shows the enhanced fitting related 
to other models. The influences of independent factors 
were as evaluated as displayed in Table 5. The p value 
of the model was found (P = 0.0168) < 0.05 indicating 
that the model was significant. The independent variable 
X2, had prominent positive effect (β2= 2.9444) on 
viscosity, while the X1 variable had very minor impact 
(β1= 0.3333) viscosity. The changing of factor (PEG 
400) X2 from -1 to +1 showed the viscosity change from 
13 cp to 21 cp.  
The contour and surface plot for viscosity were 
constructed as represented in Figure 2. It can be 
interpreted that concentration of PEG 400 and viscosity 
of the formulation were interrelated. 
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Table 5: ANOVA for response Viscosity 
 Sum of  Mean F p-value Coefficient 
Source Squares df Square Value Prob > F  
Model 56.30 5 11.26 19.68 0.0168 
(significant) 
 
Intercept[(β0)]      17.7407 
Sodium cholate [(β1)] 0.67 1 0.67 1.17 0.3593  0.3333 
PEG 400[(β2)] 52.04 1 52.04 91.12 0.0024 2.9444 
 [(β12)] 2.77 1 2.77 4.85 0.1148  0.8333 
 [(β1)
2
]
 
0.10 1 0.10 0.17 0.7056  0.2222 
[(β2)
2
] 0.75 1 0.75 1.31 0.3360  0.6111 
Residual 1.71 3 0.57    
Cor Total 58.02 8     
 
The Table 6 displayed the percentage error observed 
between the experimental value and the predicted value 
of various experimental batches. The % bias value of 
diffusion at 10 minutes was found in the range of -1.72% 
to 1.67 % and the % bias value for viscosity was found 
in the range of - 5.64% to 6.52 %. The percentage 
bias/error for both the variables were found satisfactory, 
which endorsed the model selected was successful to 
predict the response of the experimental design. The 
summary of the results of regression analysis of batches 
of xylometazoline nasal solution for full and reduced 
model was provided in Table 7. 
 
Table 6: % bias for experimental batches for xylometazoline nasal solution for pediatric use 
 
Batch 
No. 
Compositi
on of 
Sodium 
Cholate 
Compos
ition of 
PEG 
Calculated 
Value 
 0f Diff. 
Exp 
Value of 
Diff 
% Bias 
for  
Diff. 
Calculated 
Value 
 of Visc. 
Exp 
Value of 
Vis. 
% Bias for 
Visc. 
PFA1 -1 -1 64.66 65.33 1.02 14.20 13.33 6.52 
PFA2 0 -1 74.55 74.33 -0.29 14.53 14.33 -1.39 
PFA3 1 -1 90.99 90.33 -0.73 14.87 15.33 3.00 
PFA4 -1 0 65.44 64.33 -1.72 17.14 17.00 -0.82 
PFA5 0 0 75.33 75.33 0.00 17.48 18.33 4.63 
PFA6 1 0 91.77 93.33 1.67 17.81 18.33 2.83 
PFA7 -1 1 66.22 66.66 0.66 20.09 21.33 5.81 
PFA8 0 1 76.11 76.33 0.28 20.42 19.33 -5.64 
PFA9 1 1 92.55 91.66 -0.97 20.75 20.00 -3.75 
 
Table 7: Summary of the results of regression analysis of batches of pediatric xylometazoline nasal solution for 
factorial design 
Response Model β0 β1 Β2 β11 β22 β12 R
2 
% Diff. at 
10 mins. 
Full 75.4814 13.1666 0.7777 0.000 3.2777 -0.2222 0.9948 
Reduced 75.3333 13.1666 0.7777  3.2777  0.9947 
 
Viscosity 
Full 17.7407 0.3333 2.9444 -0.8333 0.2222 -0.6111 0.9704 
Reduced 17.4814 0.3333 2.9444    0.9079 
 
Optimization of experimental design 
The design of experimental model was validated by two 
check point batches. The verification for % diffusion and 
viscosity of checkpoint batches was confirmed by 
utilizing mathematics equation (3,4).  
The Table 8 depicts the results for check point batches 
for % diffusion at 10 minutes and viscosity. The Figure 
2 displays contour and surface response plots. The 
optimization of formulation was performed by utilizing 
the Design
®
 Expert software by using desirability 
approach (Figure 3). 
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Figure 3: Overlay plot of optimized formulation 
Table 8: Check point batches results for dependent variables with % bias 
Sr. 
No. 
Conc. of 
sodium 
cholate* 
Conc. of PEG 
400* 
Diffusion at 10 min (%) Viscosity (cp) 
Actual Predicted % Bias Actual Predicted % Bias 
1 -0.08 0.0 73.3 74.44 -1.55 18.0 17.71 1.61 
2 0.2 -1 76.3 77.24 -1.23 14.0 14.42 -3.00 
* Coded values are indicated 
 
The optimized formulation contained sodium cholate 
0.105 g and PEG 400 1.35 mL as displayed in Table 9. 
This formulation PFE displayed values for % diffusion 
at 10 min and viscosity is 87.33 % and 19.33 cps 
respectively. The comparision of in-vitro diffusion 
results between otrivin
®
 pediatric and batch PFE is 
revealed in Figure 4, indicating that the optimized 
formulation demonstrating superior % diffusion at 10 
minutes. (Refer supplementary Table 2). 
 
 
Figure 4: In-vitro diffusion comparison of marketed formulation and optimized batch 
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Table 9: Optimized Batch Composition (PFE) and results of market and optimized batch preparation 
Ingredients Composition 
Xylometazoline HCl 5 mg 
Sodium Cholate 0.105 g 
PEG400 1.35 ml 
Sodium CMC 0.01 g 
Glycerin 0.15 ml 
Methyl Paraben 0.0033 g 
NaCl qs 
Purified Water qs to 10 ml 
Parameters Market Formulation 
(B. No: 31090V) 
Optimized Batch 
(B. No: PFE) 
Assay ( % w/w) 99.59 ± 0.83 100.41 ± 0.89 
Clarity Clear Solution Clear Solution 
pH of solution 6.40 ± 0.0 6.50 ± 0.00 
Drug Diffusion 83.0 ± 1.00 87.33 ± 1.15 
Viscosity 4.33 ± 0.57 19.33 ± 0.57 
 
Other Evaluation parameters  
pH : 
The formulation pH for factorial design batches was 
found in the range of 6.50 ± 0.3 showing better 
compatibility at the delivery site. 
Spray Content Uniformity: 
The formulations must be assessed in its relationships of 
emitted dose content uniformity. The Table 10 data 
indicated the drug substance content sprayed within 
same container and among the different containers. The 
results are in the range of 95-102 %. 
 
Table 10: Drug substance content among different containers 
Sr. No Batch No PC1* PC2* PC3* 
1 PFE 102 % 97 % 99 % 
Drug substance content among same containers 
Sr. No Batch No S1
#
 S2
#
 S3
#
 
1 PFE 100 % 99 % 95 % 
* indicates different containers labelled PC1, PC2 and PC3 used for Spray content test. 
# indicates different sprays (S1, S2 and S3) from container PC5. 
 
Pump Delivery: 
The relevant performance from pump is primarily 
essential for precise delivery of drug to targeted part. 
This test guarantees specific dose is constantly delivered 
by the pump. The initial weight of filled nasal spray was 
15 g.  The final weight of spray system was found the 
14.5 g after 10 actuations, with the actuation volume for 
each spray as 100 μl. The results showed that the pump 
delivery of xylometazoline nasal spray formulation for 
pediatric use was satisfactory.  
 
Spray Pattern: 
The pumping performance can be estimated with the 
help of spray pattern test. This test could be impacted by 
factors such as the size and shape of the nozzle of pump, 
the design of the pump, the formulation characteristics 
etc. The ovality of spray was 1.118, while perimeter and 
area of spray pattern were found to be 57.42 mm and 
258.8 mm
2
 respectively. Image actuation graph, along 
with intensity graph for the formulation are as presented 
in Figure 5. The figure 4 endorses that the pump 
delivered the required medication appropriately without 
any concerns. 
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Figure 5: Spray pattern, Image Actuation Graph and Intensity Graph of formulation 
 
Weight Loss: 
The formulation was stored in both i.e. inverted and 
horizontal position.  Weight loss study was performed 
for stability time points of 3 and 6 months. As shown in 
Table 11, the results indicated that there was no any 
change for weight loss study demonstrating the 
reliability of packaging components. 
 
Table 11: Inverted position for net content and weight loss evaluation 
Sr. No Batch No Container Initial Wt Wt after 3 
months 
Wt after 6 months 
1 PFE 1 15 g 15 g 15 g 
2 2 15 g 15 g 15 g 
Horizontal position for net content and weight loss evaluation 
Sr. No Batch No Container Initial Wt Wt after 3 
months 
Wt after 6 months 
1 PFE 1 15 g 15 g 15 g 
2 2 15 g 15 g 15 g 
 
Priming and Repriming study 
Priming Study: 
These studies were executed to support the number of 
actuations to be suggested which essentially to be fired 
to discarded prior to the end user using the product for 
the first time and subsequent use afterwards. The 
priming study was performed on formulation nasal spray 
and the results obtained were 101.2 % and 98.1 % 
respectively for first actuation. This study referenced 
that only one actuation requirement as priming since the 
results obtained were higher than 95 %.  
Repriming study: 
Repriming study results at 5 days, 10 days and 30 days 
are as shown in Table 12. The least value for repriming 
within 5, 10 and 30 days was obtained to be 97.6 % 
while the extreme value acquired was 102.2 %. It was 
concluded that one actuation was satisfactory for 
repriming.
  
Table 12: Repriming study for 5 days 
Cont. 
No. 
Duration Repriming No of 
Actuations 
Assay Results 
1 5 d Yes 1 99.9 % 
2 5 d Yes 1 98.4 % 
Repriming study for 10 days 
1 10 d Yes 1 102.2% 
2 10 d Yes 1 98.1 % 
Repriming study for 30 days 
1 30 d Yes 1 97.6 % 
2 30 d Yes 1 100.3% 
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Droplet Size Distribution: 
The droplet size study was performed based on laser 
diffraction method. The instrument used was automatatic 
nasal actuator (Malvern Instruments,UK) further 
assembled onto spraytech. The droplet size distribution 
was carried out for five containers labelled C1 to C5, 
where each container was actuated at 3 cm distance from 
orifice of actuator. Single scan was used for performing 
droplet size distribution at fully developed spray stable 
phase. The results of median droplet size (D50) mean 
from 6 cm actuation distance are shown in Table 13. The 
results were obtained in the range of 51.63 to 58.90 µm. 
 
Table 13: Results for Droplet size (D50) distribution 
Container Number D50 Value (μm) 
Droplet size distribution 
PC1 58.90 ± 3.28 
PC2 51.63 ± 4.72 
PC3 52.42 ± 2.97 
PC4 56.59 ± 3.19 
PC5 57.77 ± 3.63 
 
Sterility: 
The sterility test of optimized formulation batch PFE 
was carried out as per USP criteria using container PC8. 
The sterility test showed no microbial growth, which 
indicated that the formulation was sterile. 
 Stability Studies: 
The stability of optimized pediatric nasal formulation 
(Batch PFE) was carried at 25 ± 2 ºC / 60 ± 5% RH for 
12 months and accelerated condition study was 
performed at 40 ± 2
o
C/ 75 ± 5% RH for 6 months. The 
results were displayed in Table 14. No significant 
change was observed in context of initial results. Batch 
number PFE also demonstrated the satisfactory 
appearance, pH, in vitro diffusion, viscosity and sterility 
at the completion of the stability study. 
 
Table 14: Results of stability study at 25 ± 2 
o
C/ 60 ± 5% RH 
Specifications Initial ( 0 m) At 3 months At 6 months At 9 months At 12 months 
Appearance Clear solution Clear solution Clear solution Clear solution Clear solution 
pH 6.5 ± 0.00 6.4 ± 0.05 6.5 ± 0.00 6.5 ± 0.00 6.4 ± 0.05 
Viscosity (cp) 19.33 ± 0.57 18.33± 0.57 18.66± 0.57 19.33± 0.57 19.33± 0.57 
Assay (%) 100.41±0.89 98.81± 0.62 99.60± 1.29 99.34± 0.72 98.86± 0.93 
% diffusion 87.33 ± 1.15 89.33± 1.52 88.33± 0.57 88.33± 1.52 90.00± 1.00 
Net content* 10 ml -- -- -- 10 ml 
Sterility* confirms -- -- -- confirms 
 Results of stability study at 40 ± 2 
o
C/ 75 ± 5% RH 
Specifications Initial ( 0 m) At 3 months At 6 months 
Appearance Clear solution Clear solution Clear solution 
pH 6.5 ± 0.00 6.5 ± 0.00 6.5 ± 0.00 
Viscosity (cp) 19.33 ± 0.57 20.66 ± 0.57 19.33 ± 0.57 
Assay (%) 100.41±0.89 99.20 ± 1.05 99.18 ± 0.42 
% diffusion 87.33 ± 1.15 89.00 ± 1.73 89.66 ± 1.52 
Net content* 10 ml -- 10 ml 
Sterility* confirms -- confirms 
*These tests were performed initially and at end point 
CONCLUSION 
The pediatric nasal spray formulation was developed by 
utilizing factorial design approach. The drug-excipient 
compatibility study endorsed no interaction between 
xylometazoline and the excipients. The 3
2
 full factorial 
design was utilized, where sodium cholate (X1) and PEG 
400 (X2) were allocated as independent factors. The 
parameters for solution formulation such as drug 
content, pH, viscosity, % diffusion, sterility and spray 
evaluation like spray content uniformity, pump delivery, 
spray pattern, and weight loss were evaluated. The 
results for spray content uniformity were in the range of 
95-102 %, while pH in the range of 6.5 ± 0.3. The 
ovality of spray was 1.118, while perimeter and area of 
spray pattern were found to be 57.42 mm and 258.8 
mm
2
 respectively for optimized formulation. The least 
value for repriming was 97.6 % while the extreme value 
was 102.2 % indicating one actuation was satisfactory 
for repriming. The results for droplet size test were 
obtained in the range of 51.63 to 58.90 µm. The 
formulation along with its container closure was 
evaluated for its stability up to 12 months at long term 
conditions. The formulated batch PFE showed better 
performance for in-vitro drug release with marketed 
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product thus providing another option for treatment of 
nasal congestion. 
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